Africa IVD Market by Product & Solution, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), End User - Forecast to 2030

Africa IVD Market by Product & Solution, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), End User - Forecast to 2030

Africa In Vitro Diagnostics Market by Product & Solution, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), End User — Forecast to 2030

The Africa IVD market is expected to grow at a CAGR of 2.8% from 2023 to 2030 to reach $1.49 billion by 2030.

After a comprehensive secondary and primary research study and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the Africa IVD market.

The high prevalence of infectious diseases, the rising burden of chronic diseases, the rising initiatives to support the healthcare sector, and the growing awareness about the importance of early disease diagnosis are the major drivers for the Africa IVD market. However, poor healthcare facilities and infrastructure in African countries are the major challenges to the market’s growth.

Based on product category, in 2023, the reagents & kits segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the frequent use of assays & kits in the detection of various chronic diseases coupled with the high burden of infectious diseases in African countries.

Based on technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to its advantages such as high sensitivity and accuracy, high throughput capability, and the rising prevalence of infectious diseases.

Based on application, in 2023, the infectious diseases segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is primarily attributed to the high prevalence of infectious diseases such as COVID-19, dengue, HIV, and Chagas disease in the region and the rising initiatives to boost testing capabilities.

Based on diagnostic approach, in 2023, the lab testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the availability of several IVD tests and the higher accuracy offered by laboratory testing.

Based on end user, in 2023, the hospitals & clinics segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the high demand for IVD diagnostics and the higher preference for hospitals as the primary center of care.

Based on geography, in 2023, South Africa is expected to account for the largest share of this market. The major share of this region is mainly attributed to the high burden of diseases, the rising geriatric population, the increasing initiatives to promote diagnostic testing, and continuous efforts to develop healthcare infrastructure and promote awareness.

The key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).

Scope of the Report

Africa IVD Market Assessment–by Product Category

Reagents & Kits
Instruments
Software & Services

Africa IVD Market Assessment–by Technology

Molecular Diagnostics
Point-of-care Diagnostics
Immunoassay/Immunochemistry
Biochemistry/Clinical Chemistry
Whole Blood Glucose Monitoring
Hematology
Microbiology
Coagulation & Hemostasis
Other IVD Technologies

Note: Other technologies include urinalysis, hybridization, and loop-mediated amplification.

Africa IVD Market Assessment–by Application

Infectious Diseases
Oncology
Diabetes
Cardiology
Nephrology
Autoimmune Disorders
Other Applications

Note: Other applications include toxicology, gastroenterology, neonatal, genetic, and neurological disorders.

Africa IVD Market Assessment–by Diagnostic Approach

Lab Testing
Point-of-care Testing
OTC/Self-testing

Africa IVD Market Assessment–by End User

Hospitals & Clinics
Diagnostic Laboratories
Home Care
Other End Users

Note: Other end users include long-term care facilities, academic & research institutes, ambulatory care centers, and transfusion laboratories.

Africa IVD Market Assessment–by Country

South Africa
Egypt
Algeria
Nigeria
Morocco
Kenya
Tunisia
Tanzania
Rest of Africa

Africa In Vitro Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2023–2030) - Report Summary

Report Metrics	Details
Years Considered	2021 - 2030
Base Year	2022
Forecast Period	2023-2030
Page Count	174
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Product Category, Technology, Application, Diagnostic Approach, and End User
Regions Covered	South Africa, Egypt, Algeria, Nigeria, Morocco, Kenya, Tunisia, Tanzania, and Rest of Africa
Key Companies Mentioned	Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).

FAQs About the Report

What is the focus of the Africa IVD market report?

The Africa IVD market report covers the market size & forecasts of various IVD products (reagents & kits, instruments, and software & services) offered by key market players based on various technologies such as immunoassay/immunochemistry, whole blood glucose monitoring, molecular diagnostics, point-of-care diagnostics, biochemistry/clinical chemistry, microbiology, hematology, coagulation & hemostasis, and other IVD technologies.

These IVD products are used for various applications, including infectious diseases, diabetes, oncology, cardiology, nephrology, autoimmune diseases, and other applications. The Africa IVD market study covers various IVD products used for lab testing, OTC/self-testing, and point-of-care testing in diagnostic laboratories, hospitals & clinics, home healthcare, and other end users.

What is the revenue generated from IVD products across Africa? At what rate is their demand expected to grow for the next 5–7 years?

The Africa IVD market is projected to reach $1.49 billion by 2030, at a CAGR of 2.8% during the forecast period.

Which product category is estimated to hold the major share of the market?

Based on product category, in 2023, the reagents & kits segment is expected to account for the largest share of the Africa IVD market.

Which technology segment is estimated to hold the major share of the market?

Based on technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the Africa IVD market.

Which application segment is projected to create more traction in the Africa IVD market?

Based on application, the cardiology segment is slated to register the fastest growth rate during the forecast period.

Which end user segment is estimated to hold the major share of the market?

Based on end user, in 2023, the hospitals & clinics testing segment is expected to account for the largest share of the Africa IVD market.

What are the key factors supporting the growth of this market?

The high prevalence of infectious diseases, the rising burden of chronic diseases, the increasing initiatives to support the healthcare sector, and the growing awareness about the importance of early disease diagnosis are the key factors driving the growth of the Africa IVD market.

Who are the major players operating in the Africa IVD Market?

The key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).